The results suggest that the glutamic and aspartic acid residues involved in calcium and phospholipid binding serve as the determinants of ANXA7 action on IP3 receptor expression and prostate cancer cell survival via the PI3K/mTOR pathway. Here, ANXA7 is linked to prostate carcinoma.